1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug β€” Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 β€” Novo Nordisk's Ozempic wins FDA label boost with CV indication β€” See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

How to gain an enemy for $2000

Discussion in 'Sage Therapeutics' started by anonymous, Oct 18, 2019 at 9:53 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Refer them to Sage Therapeutics! If someone doesn't do their due diligence when researching a job, deserves to come here now.
     

  2. anonymous

    anonymous Guest

    It’s so sad. I felt the exact opposite a year ago
     
  3. anonymous

    anonymous Guest

    I wouldn't wish this company on my worst enemy. These openings during a launch should be very telling to anyone interested. Conditions here are virulent and no one likes it here. This is a compliant lead company, but not in a good way.